Skip to main content
. 2020 Apr 28;117(18):9952–9963. doi: 10.1073/pnas.1917608117

Fig. 7.

Fig. 7.

DKK3 cleavage utilization as PD biomarker in the phase 1 study following treatment with anti-HtrA1 Fab15H6.v4.D221. The SAD stage consisted of doses of anti-HtrA1 Fab15H6.v4.D221 ranging from 1 to 20 mg (n = 15). Levels of cleaved DKK3 were assessed by Western blot in aqueous humor of patients at baseline and at multiple time points following anti-HtrA1 treatment as a biomarker of anti-HtrA1 modulation of HtrA1 protease activity. A plot of percent change from baseline for aqueous humor cleaved DKK3 by study day is shown for each treatment group.